Reviving lixivaptan

How Palladio plans to repurpose lixivaptan for ADPKD

Single-asset play Palladio Biosciences Inc. is repurposing lixivaptan as a safer alternative to Jinarc tolvaptan, a competing vasopressin 2 (V2) receptor antagonist associated with hepatotoxicity in patients with autosomal dominant polycystic kidney disease.

ADPKD is characterized by cyst formation and kidney enlargement, which can eventually lead to kidney failure. According to the company, about half of ADPKD patients require dialysis or kidney transplantation by age 60.

There are no disease-modifying therapies approved for ADPKD in the

Read the full 740 word article

User Sign In